Summary of studies with more than 300 patients correlating thrombocytosis with survival in solid tumors
| Cancer type, N . | Cutoff (per mm3) . | Prevalence, n (%) . | Study type . | Survival results (thrombocytosis vs normal) . | Reference . |
|---|---|---|---|---|---|
| Lung | |||||
| 398 | 400 000 | 86 (21.6) | Retrospective | OS: HR, 1.58 (P = .006, mva) | 31 |
| 317 | 400 000 | 64 (20.2) | Prospective | Time to progression: (P = .2, uva) | 32 |
| Chemotherapy response: 32.8% vs 56% (P = .001) | |||||
| 611 | 400 000 | 98 (16) | Retrospective | OS: HR, 1.29 (P = .0348, mva) | 33 |
| 1115 | 400 000 | 358 (32.1) | Retrospective | OS: HR, 4.24 (P < .001, mva) | 34 |
| Mesothelioma | |||||
| 336 | 400 000 | 184 (54.8) | Retrospective | OS: HR, 1.57 (P < .001, mva) | 35 |
| Breast | |||||
| 4300 | 400 000 | 161 (3.7) | Retrospective | OS: HR, 1.73 (P = .0064, mva) | 36 |
| Gynecologic | |||||
| 578 | 450 000 | 129 (22.3) | Retrospective | DFS: HR, 1.38 (P = .02, mva) | 37 |
| OS: HR, 1.45 (P = .003, mva) | |||||
| Stage I/II (n = 127); OS: HR, 5.06 (P = .008, mva) | |||||
| 3490 | Various | 709 (20.3) | Meta-analysis | OS: RR, 1.62 (P < .0001, mva) | 38 |
| Colorectal | |||||
| 453 | 300 000 | 226 (49.9) | Retrospective | OS: HR, 1.64 (P = .039, mva) | 39 |
| 636 | 370 000 | 77 (12.1) | Retrospective | OS: HR, 3.04 (P < .001, mva) | 40 |
| DFS: HR, 2.54 (P < .001, mva) | |||||
| Gastric | |||||
| 369 | 400 000 | 42 (11.4) | Retrospective | OS: HR, 2.48 (P = .015, mva) | 41 |
| Renal | |||||
| 804 | 450 000 | 63 (7.8) | Retrospective | OS: OR, 1.8 (P < .0001, mva) | 42 |
| Cancer type, N . | Cutoff (per mm3) . | Prevalence, n (%) . | Study type . | Survival results (thrombocytosis vs normal) . | Reference . |
|---|---|---|---|---|---|
| Lung | |||||
| 398 | 400 000 | 86 (21.6) | Retrospective | OS: HR, 1.58 (P = .006, mva) | 31 |
| 317 | 400 000 | 64 (20.2) | Prospective | Time to progression: (P = .2, uva) | 32 |
| Chemotherapy response: 32.8% vs 56% (P = .001) | |||||
| 611 | 400 000 | 98 (16) | Retrospective | OS: HR, 1.29 (P = .0348, mva) | 33 |
| 1115 | 400 000 | 358 (32.1) | Retrospective | OS: HR, 4.24 (P < .001, mva) | 34 |
| Mesothelioma | |||||
| 336 | 400 000 | 184 (54.8) | Retrospective | OS: HR, 1.57 (P < .001, mva) | 35 |
| Breast | |||||
| 4300 | 400 000 | 161 (3.7) | Retrospective | OS: HR, 1.73 (P = .0064, mva) | 36 |
| Gynecologic | |||||
| 578 | 450 000 | 129 (22.3) | Retrospective | DFS: HR, 1.38 (P = .02, mva) | 37 |
| OS: HR, 1.45 (P = .003, mva) | |||||
| Stage I/II (n = 127); OS: HR, 5.06 (P = .008, mva) | |||||
| 3490 | Various | 709 (20.3) | Meta-analysis | OS: RR, 1.62 (P < .0001, mva) | 38 |
| Colorectal | |||||
| 453 | 300 000 | 226 (49.9) | Retrospective | OS: HR, 1.64 (P = .039, mva) | 39 |
| 636 | 370 000 | 77 (12.1) | Retrospective | OS: HR, 3.04 (P < .001, mva) | 40 |
| DFS: HR, 2.54 (P < .001, mva) | |||||
| Gastric | |||||
| 369 | 400 000 | 42 (11.4) | Retrospective | OS: HR, 2.48 (P = .015, mva) | 41 |
| Renal | |||||
| 804 | 450 000 | 63 (7.8) | Retrospective | OS: OR, 1.8 (P < .0001, mva) | 42 |
DFS, disease-free survival; HR, hazard ratio; mva, multivariate analysis; OS, overall survival; RR, risk ratio; uva, univariate analysis.